KR102906376B1 - 항혈소판 약물 및 이의 용도 - Google Patents
항혈소판 약물 및 이의 용도Info
- Publication number
- KR102906376B1 KR102906376B1 KR1020257016343A KR20257016343A KR102906376B1 KR 102906376 B1 KR102906376 B1 KR 102906376B1 KR 1020257016343 A KR1020257016343 A KR 1020257016343A KR 20257016343 A KR20257016343 A KR 20257016343A KR 102906376 B1 KR102906376 B1 KR 102906376B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- present disclosure
- alkyl
- saturated
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/105513 | 2020-07-29 | ||
| CN2020105513 | 2020-07-29 | ||
| KR1020237007048A KR20230047425A (ko) | 2020-07-29 | 2021-07-28 | 항혈소판 약물 및 이의 용도 |
| PCT/CN2021/108875 WO2022022559A1 (en) | 2020-07-29 | 2021-07-28 | Antiplatelet drugs and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237007048A Division KR20230047425A (ko) | 2020-07-29 | 2021-07-28 | 항혈소판 약물 및 이의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20250073569A KR20250073569A (ko) | 2025-05-27 |
| KR102906376B1 true KR102906376B1 (ko) | 2025-12-30 |
Family
ID=80037185
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257016343A Active KR102906376B1 (ko) | 2020-07-29 | 2021-07-28 | 항혈소판 약물 및 이의 용도 |
| KR1020237007048A Pending KR20230047425A (ko) | 2020-07-29 | 2021-07-28 | 항혈소판 약물 및 이의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237007048A Pending KR20230047425A (ko) | 2020-07-29 | 2021-07-28 | 항혈소판 약물 및 이의 용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12410132B2 (https=) |
| EP (2) | EP4188935A4 (https=) |
| JP (1) | JP2023535815A (https=) |
| KR (2) | KR102906376B1 (https=) |
| CN (4) | CN119033782B (https=) |
| AR (1) | AR123078A1 (https=) |
| AU (1) | AU2021317436A1 (https=) |
| BR (1) | BR112023001595A2 (https=) |
| CA (1) | CA3186645A1 (https=) |
| ES (1) | ES3046366T3 (https=) |
| IL (1) | IL299979A (https=) |
| MX (1) | MX2023001232A (https=) |
| TW (1) | TW202214609A (https=) |
| WO (1) | WO2022022559A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202339745A (zh) * | 2022-01-28 | 2023-10-16 | 大陸商上海柯君醫藥科技有限公司 | 抗血小板藥物的藥物組合物及其用途 |
| CN116813532A (zh) * | 2023-06-29 | 2023-09-29 | 上海柯君医药科技有限公司 | 一种哌啶化合物的制备方法 |
| WO2025108307A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用 |
| WO2025108300A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用 |
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119176829B (zh) * | 2024-11-26 | 2025-04-15 | 上海柯君医药科技有限公司 | 一种哌啶环化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
| CN119371453A (zh) * | 2024-12-30 | 2025-01-28 | 上海柯君医药科技有限公司 | 一种抗血小板药物中间体的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119019320A (zh) | 2024-10-29 | 2024-11-26 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119192061A (zh) | 2024-11-28 | 2024-12-27 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ334389A (en) | 1996-08-28 | 2001-05-25 | Ube Industries | Cyclic amine derivatives |
| US20060019929A1 (en) * | 2004-07-07 | 2006-01-26 | Albert Friesen | Combination therapies employing platelet aggregation drugs |
| CN104379589A (zh) * | 2012-05-07 | 2015-02-25 | 塞利克斯比奥私人有限公司 | 抗血小板药剂的前药 |
| KR20150038369A (ko) * | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 디히드로피리돈 P1 |
| CN103626694A (zh) * | 2012-08-29 | 2014-03-12 | 中国药科大学 | 不饱和环胺衍生物、其制备方法及其医药用途 |
| NO2721243T3 (https=) * | 2014-10-01 | 2018-10-20 | ||
| CN106554303A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554368A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
-
2021
- 2021-07-28 CN CN202410873004.4A patent/CN119033782B/zh active Active
- 2021-07-28 IL IL299979A patent/IL299979A/en unknown
- 2021-07-28 CN CN202411716601.2A patent/CN119552111B/zh active Active
- 2021-07-28 MX MX2023001232A patent/MX2023001232A/es unknown
- 2021-07-28 BR BR112023001595A patent/BR112023001595A2/pt unknown
- 2021-07-28 KR KR1020257016343A patent/KR102906376B1/ko active Active
- 2021-07-28 US US18/018,576 patent/US12410132B2/en active Active
- 2021-07-28 WO PCT/CN2021/108875 patent/WO2022022559A1/en not_active Ceased
- 2021-07-28 ES ES24156405T patent/ES3046366T3/es active Active
- 2021-07-28 EP EP21851193.9A patent/EP4188935A4/en active Pending
- 2021-07-28 CN CN202311275197.5A patent/CN117343000A/zh active Pending
- 2021-07-28 KR KR1020237007048A patent/KR20230047425A/ko active Pending
- 2021-07-28 CA CA3186645A patent/CA3186645A1/en active Pending
- 2021-07-28 CN CN202180058245.8A patent/CN116194459A/zh active Pending
- 2021-07-28 EP EP24156405.3A patent/EP4342532B1/en active Active
- 2021-07-28 AU AU2021317436A patent/AU2021317436A1/en active Pending
- 2021-07-28 JP JP2023506150A patent/JP2023535815A/ja active Pending
- 2021-07-29 AR ARP210102107A patent/AR123078A1/es unknown
- 2021-07-29 TW TW110127818A patent/TW202214609A/zh unknown
-
2025
- 2025-07-08 US US19/262,108 patent/US20250333382A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119019320A (zh) | 2024-10-29 | 2024-11-26 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119192061A (zh) | 2024-11-28 | 2024-12-27 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188935A4 (en) | 2024-07-17 |
| EP4342532B1 (en) | 2025-09-03 |
| KR20230047425A (ko) | 2023-04-07 |
| US20240279178A1 (en) | 2024-08-22 |
| MX2023001232A (es) | 2023-05-15 |
| EP4342532A2 (en) | 2024-03-27 |
| CN116194459A (zh) | 2023-05-30 |
| EP4342532C0 (en) | 2025-09-03 |
| AU2021317436A1 (en) | 2023-02-23 |
| CA3186645A1 (en) | 2022-02-03 |
| IL299979A (en) | 2023-03-01 |
| US12410132B2 (en) | 2025-09-09 |
| WO2022022559A1 (en) | 2022-02-03 |
| ES3046366T3 (en) | 2025-12-01 |
| CN117343000A (zh) | 2024-01-05 |
| EP4342532A3 (en) | 2024-07-17 |
| KR20250073569A (ko) | 2025-05-27 |
| JP2023535815A (ja) | 2023-08-21 |
| US20250333382A1 (en) | 2025-10-30 |
| CN119552111B (zh) | 2026-01-02 |
| TW202214609A (zh) | 2022-04-16 |
| CN119033782A (zh) | 2024-11-29 |
| CN119552111A (zh) | 2025-03-04 |
| BR112023001595A2 (pt) | 2023-04-04 |
| EP4188935A1 (en) | 2023-06-07 |
| CN119033782B (zh) | 2025-04-25 |
| AR123078A1 (es) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102906376B1 (ko) | 항혈소판 약물 및 이의 용도 | |
| EP4382530A1 (en) | Shp2 inhibitor, pharmaceutical composition comprising same, and application thereof | |
| JP2025081322A (ja) | オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 | |
| JPH08507049A (ja) | 低脂血症性化合物１，４−チアゼピン | |
| KR20240142492A (ko) | 항혈소판 약물의 약학적 조성물 및 이의 용도 | |
| CA2926830A1 (en) | Thiazolopyrimidinones as modulators of nmda receptor activity | |
| AU2021273001A1 (en) | ENPP1 modulators and uses thereof | |
| WO2023125825A1 (en) | Anticoronviral compounds and compositions and uses thereof | |
| EP2616460B1 (en) | Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine. | |
| EP2900664B1 (en) | Crystalline forms of dihydropyrimidine derivatives | |
| CN115677507B (zh) | 氟比洛芬衍生物及其在药物中的应用 | |
| RU2841656C1 (ru) | Антитромбоцитарные лекарственные средства и их применение | |
| US11834413B2 (en) | Antiplatelet drugs and uses thereof | |
| KR102865307B1 (ko) | 수용체 억제제, 이를 포함하는 약학적 조성물 및 그 용도 | |
| HK40117914B (zh) | 抗血小板药物和其用途 | |
| HK40117914A (zh) | 抗血小板药物和其用途 | |
| HK40090099A (zh) | 抗血小板药物和其用途 | |
| CS142991A3 (en) | Alpha-oxopyrrolo/2,3-b/indolacetic acids, their esters, amides and analogs, process for their preparation and their application as medicaments | |
| EA049888B1 (ru) | Трициклическое дигидроимидазопиримидоновое производное, способ его получения, его фармацевтическая композиция и применение | |
| HK1207081B (en) | Crystalline forms of dihydropyrimidine derivatives | |
| HK1185878B (en) | Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A302 | Request for accelerated examination | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PA0302 | Request for accelerated examination |
St.27 status event code: A-1-2-D10-D17-exm-PA0302 St.27 status event code: A-1-2-D10-D16-exm-PA0302 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |